Pharmaceutical Firms

Budget 2026: Customs duty relief to make cancer, rare disease drugs cheaper

A customs duty exemption on select high-cost cancer and rare disease therapies is expected to lower treatment costs for patients while supporting demand for multinational and domestic pharma companies

Budget 2026: Pharma dept prescribes PLI boost for bulk drug output

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production

Budget 2026: Biopharma Shakti plan aims to make India a biologics hub

Union Budget 2026: Finance Minister Nirmala Sitharaman unveils Biopharma Shakti, a ₹10,000 crore, five-year plan to boost domestic biologics, biosimilars, clinical trials and regulatory capacity

Strides Pharma Q3FY26 results: Net profit doubles to ₹208.12 cr

Strides Pharma Science Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 208.12 crore in the third quarter ended December 31, 2025 on the back of robust sales growth and one time income on sale of property. The company had posted a consolidated net profit of Rs 90.04 crore in the corresponding quarter last fiscal, Strides Pharma Science Ltd said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,194.65 crore as against Rs 1,153.67 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 1,052.7 crore as compared to Rs 1,043.96 crore in the same period a year ago, the company said. The company said during the third quarter it sold its investment property consisting of land and building for a consideration of Rs 112.87 crore and recorded a profit of Rs 102.14 crore as other income. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur, ...

Q3FY26 preview: Strong domestic sales to lift revenues for pharma firms

Strong domestic sales are expected to lift Q3FY26 pharma revenues by 8-11%, while US generic Revlimid impacts weigh on margins. Hospitals and diagnostics outperform, with 20-22% revenue growth

Brazil, Nigeria emerging as key export destinations for Indian pharma firms

Brazil and Nigeria are emerging as key export destinations for Indian pharmaceutical firms amid global economic uncertainties, according to the commerce ministry data. Nigeria emerged as one of the fastest growing destinations, adding USD 179 million in exports and contributing over 14 per cent to the total export growth during the first eight months of this fiscal year. During April-November FY26, Brazil also recorded an increase of nearly USD 100 million exports, the data showed. "These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India's role as a preferred supplier to high growth demand intensive regions," an official said. The country's pharmaceutical exports rose by 6.5 per cent to USD 20.48 billion during April-November 2025-26. The data also showed that the US continues to be the single largest destination, accounting for over 31 per cent of exports in April-November 2025, while the overall gro

Cipla slips 5%, hits nine-month low; why pharma stock under pressure?

In the past seven trading days, the stock price of Cipla has slipped 11 per cent from ₹1,530.25 hit on January 1, 2026.

Biocon raises ₹4,150 crore via QIP issue on strong investor demand

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon

Indian pharma companies see sharp drop in adverse USFDA findings in 2025

OAI cases nearly halve in 2025, overall inspection volumes also fell 25%

Antique prefers domestic-focused pharma firms; resumes coverage on 4 stocks

Antique resumed coverage on Torrent Pharma with a 'buy' rating, Cipla and Dr Reddy's Lab with 'hold' ratings, and Concord Biotech with a 'buy' rating

Synergy gains from stake purchase positive for pharma major Biocon

Brokerages say Biocon's move to fully acquire Biocon Biologics simplifies structure and unlocks value, but near-term stock pressure likely due to dilution and fundraising

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Can Ozempic trigger depression or suicidal thoughts? Australia weighs in

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

Sun Pharma unit to invest ₹3,000 cr for new plant in Madhya Pradesh

A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based drug major said in a filing on Tuesday. Shares of Sun Pharma on Wednesday ended 0.43 per cent higher at Rs 1,805.70 apiece on BSE.

Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Pharma units likely to face action for Schedule M violations: Experts

The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators

Pfizer signs deal with Metsea after bidding war with Novo Nordisk

The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences on Thursday said the US health regulator has granted Orphan Drug Designation (ODD) to Desidustat, a novel product for the treatment of beta-thalassemia. The US Food and Drug Administration (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia," Zydus Lifesciences MD Sharvil Patel said in a regulatory filing. Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications. Treatment for people with beta thalassaemia often requires lifelong regimens of chronic blood transfusions for survival and treatment for iron overload due to the transfusions. Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) an

Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals